OTCMKTS:ELOXD Eloxx Pharmaceuticals (ELOXD) Stock Price, News & Analysis $6.20 0.00 (0.00%) As of 08/12/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsSEC FilingsBuy This Stock About Eloxx Pharmaceuticals Stock (OTCMKTS:ELOXD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eloxx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.20▼$6.2050-Day Range$6.20▼$9.0052-Week Range$0.00▼$10.00VolumeN/AAverage Volume3,320 shsMarket Capitalization$2.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) is a clinical‐stage biopharmaceutical company focused on developing precision medicines for rare genetic diseases caused by nonsense mutations. Its lead candidate, ELX-02, is a novel small molecule designed to enable ribosomal read-through of premature stop codons and restore production of full-length, functional proteins. The company’s initial therapeutic targets include cystic fibrosis and cystinosis, with ELX-02 advancing through Phase 2 clinical studies in cystic fibrosis and Phase 1/2 trials in cystinosis. In addition to ELX-02, Eloxx is advancing second-generation read-through compounds in its discovery pipeline to broaden treatment opportunities for patients with other nonsense mutation-driven disorders. The company’s research and development efforts leverage proprietary chemistry to optimize efficacy and safety profiles, and it has established clinical sites across North America and Europe to support multi-regional trials. Eloxx aims to address a high unmet medical need by providing targeted therapies where few or no approved options exist. Founded in 2016 and incorporated in Delaware, Eloxx Pharmaceuticals is headquartered in Mamaroneck, New York. The company’s management team includes seasoned biotechnology executives with deep expertise in rare disease drug development, clinical operations and regulatory affairs. Eloxx is committed to advancing its pipeline through clinical milestones and to forging strategic collaborations that can accelerate development timelines and expand patient access worldwide. AI Generated. May Contain Errors. Read More Receive ELOXD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELOXD Stock News HeadlinesEloxx Pharmaceuticals, Inc.: Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 12 at 1:37 PM | finanznachrichten.deEloxx Pharmaceuticals (ELOXD) Projected to Announce Quarterly Earnings on MondayAugust 9, 2026 | americanbankingnews.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.August 13 at 1:00 AM | Chaikin Analytics (Ad)Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to NasdaqJune 8, 2026 | prnewswire.comEloxx Pharmaceuticals Inc.May 24, 2026 | barrons.comEloxx Pharmaceuticals Inc. (ELOX) SEC FilingsMay 21, 2026 | nasdaq.comEloxx Pharmaceuticals Delays Form 10-Q FilingAugust 15, 2025 | msn.comEloxx Pharmaceuticals Announces Key Corporate AccomplishmentsNovember 12, 2024 | tmcnet.comSee More Headlines ELOXD Stock Analysis - Frequently Asked Questions How have ELOXD shares performed this year? Eloxx Pharmaceuticals' stock was trading at $0.0011 at the beginning of 2026. Since then, ELOXD shares have increased by 563,536.4% and is now trading at $6.20. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (OTCMKTS:ELOXD) announced its quarterly earnings results on Monday, April, 3rd. The company reported ($32.12) earnings per share for the quarter, beating the consensus estimate of ($32.67) by $0.55. When did Eloxx Pharmaceuticals' stock split? Eloxx Pharmaceuticals's stock reverse split before market open on Monday, June 1st 2026.The 1-11 reverse split was announced on Monday, June 1st 2026. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOXD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eloxx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eloxx Pharmaceuticals investors own include Tesla (TSLA), ADMA Biologics (ADMA), Adverum Biotechnologies (ADVM), Assertio (ASRT), Fulcrum Therapeutics (FULC), Akebia Therapeutics (AKBA). Company Calendar Last Earnings4/03/2023Today8/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ELOXD Previous SymbolNASDAQ:ELOX CIK1035354 Webwww.eloxxpharma.com Phone(781) 577-5300Fax908-864-4440Employees30Year Founded2013Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$6.36 million Price / Sales0.45 Cash FlowN/A Price / Cash FlowN/A Book Value($85.17) per share Price / Book-0.07Miscellaneous Outstanding Shares461,000Free Float342,000Market Cap$2.86 million OptionableNot Optionable Beta-1,932.72 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:ELOXD) was last updated on 8/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
